Autoimmune Drugs Market size to grow by USD 29,314.5 million between 2022 and 2027; AbbVie Inc., and AdvaCare Pharma among others, identified as key vendors

NEW YORK, May 19, 2023 /PRNewswire/ — The autoimmune drugs market size is set to grow by USD 29314.5 million between 2022 and 2027 and register a CAGR of 6.39%, according to Technavio’s latest market research report. With a focus on identifying dominant industry influencers, Technavio’s reports present a detailed study by way of synthesis, and summation of data from multiple sources. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.

Discover market potential and make informed business decisions based on qualitative and quantitative evidence highlighted in Technavio reports Read our Sample Report

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AbbVie Inc., AdvaCare Pharma, Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cardinal Health Inc., Delphis Pharmaceutical India, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Medexus Pharmaceuticals Inc., Parvus Therapeutics Inc., Prometheus Laboratories Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Wellona Pharma are some of the major market participants. The Strong R and D pipeline, the targeted therapeutic mechanism of biologics, and the introduction of affordable biosimilars will offer immense growth opportunities. To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments while maintaining their positions in the slow-growing segments.

Autoimmune Drugs Market 2023-2027: Segmentation

• Distribution Channel 
• Hospital
• Pharmacy
• Drug Store/Retail Pharmacy
• Online
• Therapy area 
• Rheumatoid arthritis: The market share growth by the rheumatoid arthritis segment will be significant during the forecast period. The rheumatoid arthritis segment was valued at USD 25,096.41 million in 2017 and continued to grow until 2021.
• Multiple sclerosis
• Psoriasis
• Inflammatory bowel disease
• Others
• Geography 
• North America: North America is estimated to contribute 51% to the growth of the global market during the forecast period. The US is the key country in North America, being a leader in the global market. The availability of advanced technical procedures for disease diagnosis and management, better healthcare awareness, and reimbursement policies for highly prevalent diseases, including autoimfmune diseases, has resulted in the US being the biggest market in the Americas.
• Europe
• Asia
• Rest Of World (ROW)

Receive our market sample report now to gain access to detailed analysis on the autoimmune drugs market: https://www.technavio.com/talk-to-us?report=IRTNTR70662

Autoimmune Drugs Market 2023-2027: Vendor Analysis and Scope

Some of the major vendors of the autoimmune drugs market include AbbVie Inc., AdvaCare Pharma, Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cardinal Health Inc., Delphis Pharmaceutical India, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Medexus Pharmaceuticals Inc., Parvus Therapeutics Inc., Prometheus Laboratories Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Wellona Pharma. To help businesses improve their market position, Technavio’s report provides a detailed analysis of around 15+ vendors operating in the market.

abbvie.com- The company offers siding solutions such as Boral TruExterior Siding.

advacarepharma.com- The company offers siding solutions such as Vinyl Siding.

amgen.com- The company offers siding solutions and related products such as UrbanPro fibre cement sheet.

The report also covers the following areas:

Market Driver

• Strong R and D pipeline
• Targeted therapeutic mechanism of biologics
• Introduction of affordable biosimilars

Market Trend

• Reduction in cost of autoimmune drugs
• Market dominance by TNF-alpha inhibitors
• Development and approval of new drugs

Market Challenges

• High cost of biologics
• Limitation of autoimmune disease diagnostics
• Reimbursement challenges of autoimmune drugs

Get lifetime access to our Technavio Insights. Subscribe now to our most popular “Lite Plan” billed annually at USD 5000. View 3 reports monthly and Download 3 Reports Annually!

Autoimmune Drugs Market 2023-2027: Key Highlights

• CAGR of the market during the forecast period 2023-2027
• Detailed information on factors that will assist autoimmune drugs market growth during the next five years
• Estimation of the autoimmune drugs market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the autoimmune drugs market
• Analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of autoimmune drugs market vendors

Related Reports:

Protein Therapeutics Market- The protein therapeutics market size is estimated to grow at a CAGR of 9.14% between 2022 and 2027. The market size is forecast to increase by USD 153.56 billion.

Cardiovascular Therapeutics Market- The cardiovascular therapeutics market size is estimated to grow at a CAGR of 7.32% between 2022 and 2027. The cardiovascular therapeutics market size is forecast to increase by USD 37.77 billion.

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy Area
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global autoimmune drugs market 2017 – 2021
• Exhibit 18: Historic Market Size – Data Table on Global autoimmune drugs market 2017 – 2021 ($ million)

• 4.2 Therapy area Segment Analysis 2017 – 2021
• Exhibit 19: Historic Market Size – Therapy area Segment 2017 – 2021 ($ million)

• 4.3 Distribution channel Segment Analysis 2017 – 2021
• Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 – 2021
• Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)

• 4.5 Country Segment Analysis 2017 – 2021
• Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis – Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition – Five forces 2022 and 2027

6 Market Segmentation by Therapy Area

• 6.1 Market segments 
• Exhibit 30: Chart on Therapy Area – Market share 2022-2027 (%)
• Exhibit 31: Data Table on Therapy Area – Market share 2022-2027 (%)

• 6.2 Comparison by Therapy Area 
• Exhibit 32: Chart on Comparison by Therapy Area
• Exhibit 33: Data Table on Comparison by Therapy Area

• 6.3 Rheumatoid arthritis – Market size and forecast 2022-2027 
• Exhibit 34: Chart on Rheumatoid arthritis – Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Rheumatoid arthritis – Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Rheumatoid arthritis – Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Rheumatoid arthritis – Year-over-year growth 2022-2027 (%)

• 6.4 Multiple sclerosis – Market size and forecast 2022-2027 
• Exhibit 38: Chart on Multiple sclerosis – Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Multiple sclerosis – Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Multiple sclerosis – Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Multiple sclerosis – Year-over-year growth 2022-2027 (%)

• 6.5 Psoriasis – Market size and forecast 2022-2027
• Exhibit 42: Chart on Psoriasis – Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Psoriasis – Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Psoriasis – Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Psoriasis – Year-over-year growth 2022-2027 (%)

• 6.6 Inflammatory bowel disease – Market size and forecast 2022-2027 
• Exhibit 46: Chart on Inflammatory bowel disease – Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Inflammatory bowel disease – Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Inflammatory bowel disease – Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Inflammatory bowel disease – Year-over-year growth 2022-2027 (%)

• 6.7 Others – Market size and forecast 2022-2027
• Exhibit 50: Chart on Others – Market size and forecast 2022-2027 ($ million)
• Exhibit 51: Data Table on Others – Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Chart on Others – Year-over-year growth 2022-2027 (%)
• Exhibit 53: Data Table on Others – Year-over-year growth 2022-2027 (%)

• 6.8 Market opportunity by Therapy Area 
• Exhibit 54: Market opportunity by Therapy Area ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments 
• Exhibit 55: Chart on Distribution Channel – Market share 2022-2027 (%)
• Exhibit 56: Data Table on Distribution Channel – Market share 2022-2027 (%)

• 7.2 Comparison by Distribution Channel 
• Exhibit 57: Chart on Comparison by Distribution Channel
• Exhibit 58: Data Table on Comparison by Distribution Channel

• 7.3 Hospital – Market size and forecast 2022-2027
• Exhibit 59: Chart on Hospital – Market size and forecast 2022-2027 ($ million)
• Exhibit 60: Data Table on Hospital – Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Chart on Hospital – Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on Hospital – Year-over-year growth 2022-2027 (%)

• 7.4 Pharmacy – Market size and forecast 2022-2027
• Exhibit 63: Chart on Pharmacy – Market size and forecast 2022-2027 ($ million)
• Exhibit 64: Data Table on Pharmacy – Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Chart on Pharmacy – Year-over-year growth 2022-2027 (%)
• Exhibit 66: Data Table on Pharmacy – Year-over-year growth 2022-2027 (%)

• 7.5 Drug store/Retail pharmacy – Market size and forecast 2022-2027 
• Exhibit 67: Chart on Drug store/Retail pharmacy – Market size and forecast 2022-2027 ($ million)
• Exhibit 68: Data Table on Drug store/Retail pharmacy – Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Chart on Drug store/Retail pharmacy – Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on Drug store/Retail pharmacy – Year-over-year growth 2022-2027 (%)

• 7.6 Online – Market size and forecast 2022-2027
• Exhibit 71: Chart on Online – Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on Online – Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on Online – Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Online – Year-over-year growth 2022-2027 (%)

• 7.7 Market opportunity by Distribution Channel
• Exhibit 75: Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 76: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 77: Chart on Market share by geography 2022-2027 (%)
• Exhibit 78: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 79: Chart on Geographic comparison
• Exhibit 80: Data Table on Geographic comparison

• 9.3 North America – Market size and forecast 2022-2027
• Exhibit 81: Chart on North America – Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on North America – Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on North America – Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on North America – Year-over-year growth 2022-2027 (%)

• 9.4 Europe – Market size and forecast 2022-2027
• Exhibit 85: Chart on Europe – Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on Europe – Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on Europe – Year-over-year growth 2022-2027 (%)

• 9.5 Asia – Market size and forecast 2022-2027
• Exhibit 89: Chart on Asia – Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on Asia – Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Asia – Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) – Market size and forecast 2022-2027 
• Exhibit 93: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)

• 9.7 US – Market size and forecast 2022-2027
• Exhibit 97: Chart on US – Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on US – Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on US – Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on US – Year-over-year growth 2022-2027 (%)

• 9.8 Germany – Market size and forecast 2022-2027
• Exhibit 101: Chart on Germany – Market size and forecast 2022-2027 ($ million)
• Exhibit 102: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
• Exhibit 103: Chart on Germany – Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on Germany – Year-over-year growth 2022-2027 (%)

• 9.9 Canada – Market size and forecast 2022-2027
• Exhibit 105: Chart on Canada – Market size and forecast 2022-2027 ($ million)
• Exhibit 106: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
• Exhibit 107: Chart on Canada – Year-over-year growth 2022-2027 (%)
• Exhibit 108: Data Table on Canada – Year-over-year growth 2022-2027 (%)

• 9.10 China – Market size and forecast 2022-2027
• Exhibit 109: Chart on China – Market size and forecast 2022-2027 ($ million)
• Exhibit 110: Data Table on China – Market size and forecast 2022-2027 ($ million)
• Exhibit 111: Chart on China – Year-over-year growth 2022-2027 (%)
• Exhibit 112: Data Table on China – Year-over-year growth 2022-2027 (%)

• 9.11 UK – Market size and forecast 2022-2027
• Exhibit 113: Chart on UK – Market size and forecast 2022-2027 ($ million)
• Exhibit 114: Data Table on UK – Market size and forecast 2022-2027 ($ million)
• Exhibit 115: Chart on UK – Year-over-year growth 2022-2027 (%)
• Exhibit 116: Data Table on UK – Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 117: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.3 Impact of drivers and challenges 
• Exhibit 118: Impact of drivers and challenges in 2022 and 2027

11 Vendor Landscape

• 11.2 Vendor landscape 
• Exhibit 119: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 120: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 121: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 122: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 123: Matrix on vendor position and classification

• 12.3 AbbVie Inc. 
• Exhibit 124: AbbVie Inc. – Overview
• Exhibit 125: AbbVie Inc. – Product / Service
• Exhibit 126: AbbVie Inc. – Key news
• Exhibit 127: AbbVie Inc. – Key offerings

• 12.4 Amgen Inc. 
• Exhibit 128: Amgen Inc. – Overview
• Exhibit 129: Amgen Inc. – Product / Service
• Exhibit 130: Amgen Inc. – Key offerings

• 12.5 AstraZeneca Plc 
• Exhibit 131: AstraZeneca Plc – Overview
• Exhibit 132: AstraZeneca Plc – Product / Service
• Exhibit 133: AstraZeneca Plc – Key news
• Exhibit 134: AstraZeneca Plc – Key offerings

• 12.6 Bristol Myers Squibb Co. 
• Exhibit 135: Bristol Myers Squibb Co. – Overview
• Exhibit 136: Bristol Myers Squibb Co. – Product / Service
• Exhibit 137: Bristol Myers Squibb Co. – Key news
• Exhibit 138: Bristol Myers Squibb Co. – Key offerings

• 12.7 Cardinal Health Inc. 
• Exhibit 139: Cardinal Health Inc. – Overview
• Exhibit 140: Cardinal Health Inc. – Business segments
• Exhibit 141: Cardinal Health Inc. – Key news
• Exhibit 142: Cardinal Health Inc. – Key offerings
• Exhibit 143: Cardinal Health Inc. – Segment focus

• 12.8 Delphis Pharmaceutical India 
• Exhibit 144: Delphis Pharmaceutical India – Overview
• Exhibit 145: Delphis Pharmaceutical India – Product / Service
• Exhibit 146: Delphis Pharmaceutical India – Key offerings

• 12.9 Eli Lilly and Co. 
• Exhibit 147: Eli Lilly and Co. – Overview
• Exhibit 148: Eli Lilly and Co. – Product / Service
• Exhibit 149: Eli Lilly and Co. – Key offerings

• 12.10 F. Hoffmann La Roche Ltd. 
• Exhibit 150: F. Hoffmann La Roche Ltd. – Overview
• Exhibit 151: F. Hoffmann La Roche Ltd. – Business segments
• Exhibit 152: F. Hoffmann La Roche Ltd. – Key news
• Exhibit 153: F. Hoffmann La Roche Ltd. – Key offerings
• Exhibit 154: F. Hoffmann La Roche Ltd. – Segment focus

• 12.11 GlaxoSmithKline Plc 
• Exhibit 155: GlaxoSmithKline Plc – Overview
• Exhibit 156: GlaxoSmithKline Plc – Business segments
• Exhibit 157: GlaxoSmithKline Plc – Key offerings
• Exhibit 158: GlaxoSmithKline Plc – Segment focus

• 12.12 Hikma Pharmaceuticals Plc 
• Exhibit 159: Hikma Pharmaceuticals Plc – Overview
• Exhibit 160: Hikma Pharmaceuticals Plc – Business segments
• Exhibit 161: Hikma Pharmaceuticals Plc – Key offerings
• Exhibit 162: Hikma Pharmaceuticals Plc – Segment focus

• 12.13 Johnson and Johnson 
• Exhibit 163: Johnson and Johnson – Overview
• Exhibit 164: Johnson and Johnson – Business segments
• Exhibit 165: Johnson and Johnson – Key news
• Exhibit 166: Johnson and Johnson – Key offerings
• Exhibit 167: Johnson and Johnson – Segment focus

• 12.14 Parvus Therapeutics Inc. 
• Exhibit 168: Parvus Therapeutics Inc. – Overview
• Exhibit 169: Parvus Therapeutics Inc. – Product / Service
• Exhibit 170: Parvus Therapeutics Inc. – Key offerings

• 12.15 Sanofi SA 
• Exhibit 171: Sanofi SA – Overview
• Exhibit 172: Sanofi SA – Business segments
• Exhibit 173: Sanofi SA – Key news
• Exhibit 174: Sanofi SA – Key offerings
• Exhibit 175: Sanofi SA – Segment focus

• 12.16 Takeda Pharmaceutical Co. Ltd. 
• Exhibit 176: Takeda Pharmaceutical Co. Ltd. – Overview
• Exhibit 177: Takeda Pharmaceutical Co. Ltd. – Product / Service
• Exhibit 178: Takeda Pharmaceutical Co. Ltd. – Key news
• Exhibit 179: Takeda Pharmaceutical Co. Ltd. – Key offerings

• 12.17 Teva Pharmaceutical Industries Ltd.
• Exhibit 180: Teva Pharmaceutical Industries Ltd. – Overview
• Exhibit 181: Teva Pharmaceutical Industries Ltd. – Business segments
• Exhibit 182: Teva Pharmaceutical Industries Ltd. – Key news
• Exhibit 183: Teva Pharmaceutical Industries Ltd. – Key offerings
• Exhibit 184: Teva Pharmaceutical Industries Ltd. – Segment focus

13 Appendix

• 13.1 Scope of the report 

• 13.2 Inclusions and exclusions checklist
• Exhibit 185: Inclusions checklist
• Exhibit 186: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 187: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 188: Research methodology
• Exhibit 189: Validation techniques employed for market sizing
• Exhibit 190: Information sources

• 13.5 List of abbreviations 
• Exhibit 191: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio